Eldridge George A 4
4 · Aerovate Therapeutics, Inc. · Filed Mar 14, 2024
Insider Transaction Report
Form 4
Eldridge George A
See Remarks
Transactions
- Exercise/Conversion
Common Stock
2024-03-12$2.14/sh+2,051$4,389→ 4,011 total - Exercise/Conversion
Common Stock
2024-03-13$2.14/sh+2,016$4,314→ 3,976 total - Sale
Common Stock
2024-03-12$25.05/sh−2,051$51,370→ 1,960 total - Sale
Common Stock
2024-03-13$25.02/sh−2,016$50,445→ 1,960 total - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-13−2,016→ 51,263 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (2,016 underlying) - Exercise/Conversion
Stock Option (Right to Buy)
2024-03-12−2,051→ 53,279 totalExercise: $2.14Exp: 2031-04-01→ Common Stock (2,051 underlying)
Footnotes (4)
- [F1]This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 17, 2023.
- [F2]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.19, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F3]The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $25.00 to $25.08, inclusive. Full information regarding the number of shares sold at each separate price can be furnished to the SEC staff upon request.
- [F4]A total of 98,676 shares subject to an employee stock option were granted on April 2, 2021, with 25% of this option vested on June 4, 2022, and the remainder vesting in 36 substantially equal monthly installments thereafter.